Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care
Monday, June 2, 2014 - 03:05
in Health & Medicine
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study.